GeneTex

antibody

VEGFR-2 antibody [KDR-2 or 260.4] (Biotin)

GTX10975

50.00μl

289 USD

monoclonal

mouse

biotin

KDR-2 or 260.4

western blot, ELISA, immunohistochemistry, FACS

GTX10975

VEGFR-2 antibody [KDR-2 or 260.4] (Biotin)

Mouse

Monoclonal

Biotin

Primary antibody

50.00μl

289 USD

KDR-2 or 260.4

IgG1

Biotin-conjugated mouse monoclonal antibody [KDR - 2 or 260.4] to VEGFR-2

Hu

Vascular endothelial growth factor (VEGF), also called vasculotropin (VAS) and vascular permeability factor (VPF), is a member of a family of endothelial cell mitogens and angiogenic factors. VEGF is a homodimeric heparin-binding glycoprotein, which specifically stimulates the proliferation of endothelial cells isolated from both small and large vessels. These include endothelial cells from adrenal cortex, cerebral cortex, fetal and adult aorta and human umbilical vein. The mitogenic activity of VEGF appears to be stimulated by specific VEGF receptors (160-200 kDa) which can be found on the surface of various endothelial cells. VEGF binds to two structurally similar receptor tyrosine kinases; Flt17(fms-like tyrosine kinase 1, also known as VEGF Receptor 1), and KDR8 (kinase-insert domain containing receptor, also known as VEGF Receptor 2). The homologous gene for the human KDR gene is mouse Flk1 (fetal liver kinase 1) and rat TKrc Both receptors are members of a superfamily of receptor tyrosine kinases (RTKs) which include PDGF receptor, c-fms, M-CSF receptor and c-kit - the receptor for stem-cell factor. The KDR gene has been mapped to human chromosome 4q11-q12, which is the same locus of PDGF receptor and c-kit. The extracellular domains of KDR/Flk1 and Flt1 (approx. 90 kDa), have seven immunoglobulin-like domains and belong to the class III RTKs. This family includes also Flt4, which shares a high homology with the two VEGF receptors. Studies using KDR and Flt1 stably transfected endothelial cell lines have shown that these two receptors exhibit different affinities to VEGF and mediate different responses. KDR expressing cells show striking changes in cell morphology, actin reorganization and membrane ruffling, chemotaxis and mitogenicity in response to VEGF, while Flt1 expressing cells lack such responses. Both KDR and Flt1 are phosphorylated in response to VEGF, however KDR much more efficiently. KDR/Flk1 does not respond to placental growth factor (PlGF), a VEGF related growth factor, while Flt1 binds PlGF specifically. The expression pattern of the two receptors is somewhat different; Flt1 is predominately expressed in human placenta and human vascular endothelial cells, while KDR is more widely expressed in all vessel-derived endothelial cells but low in human and fetal bovine placenta. Both VEGF receptors (KDR and Flt1) are upregulated in human fetal and in adult kidney. It has been suggested that in human postnatal hematopoietic tissues, 0.1% to 0.5% of CD34+ cells express VEGF Receptor 2/KDR; pluripotent hematopoietic stem cells (HSCs) were found to be restricted to the CD34+KDR+ cell fraction, while lineage-committed hematopoietic progenitor cells (HPCs) were found in the CD34+KDR- subset. Antibodies that react specifically with VEGF receptors are useful for the study of the specific differential tissue expression and intracellular localization of the receptor in normal and neoplastic tissue.

Recombinant extracellular fragment (Human).

This antibody does not recognize VEGF Receptor 1, VEGF Receptor 3 or platelet-derived growth factor receptor beta (PDGF-R1).

Preservative: 15mM sodium azide. Constituents: 0.01M PBS, 1% BSA. pH 7.4

ELISA, FACS, IHC, WB

1.1mg/ml

Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.